Interventional procedure overview of transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine
Closed for comments This consultation ended on at Request commenting lead permission
The evidence assessed
Rapid review of literature
The medical literature was searched to identify studies and reviews relevant to transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. The following databases were searched, covering the period from their start to 16-03-2021: MEDLINE, PREMEDLINE, EMBASE, Cochrane Library and other databases. Trial registries and the Internet were also searched. No language restriction was applied to the searches (see the literature search strategy). Relevant published studies identified during consultation or resolution that are published after this date may also be considered for inclusion.
The inclusion criteria were applied to the abstracts identified by the literature search. Where selection criteria could not be determined from the abstracts the full paper was retrieved.
Characteristic | Criteria |
|---|---|
Publication type | Clinical studies were included. Emphasis was placed on identifying good quality studies. Abstracts were excluded where no clinical outcomes were reported, or where the paper was a review, editorial, or a laboratory or animal study. Conference abstracts were also excluded because of the difficulty of appraising study methodology, unless they reported specific adverse events that were not available in the published literature. |
Patient | People with migraine. |
Intervention/test | Transcutaneous electrical stimulation of the supraorbital nerve for prevention and treatment. |
Outcome | Articles were retrieved if the abstract contained information relevant to the safety, efficacy or both. |
Language | Non-English-language articles were excluded unless they were thought to add substantively to the English-language evidence base. |
List of studies included in the IP overview
This IP overview is based on 1,170 people from 2 RCTs, 3 case series and 1 observational survey for acute treatment of migraine. For prevention of migraine, it is based on 3,229 people from 4 RCTs, 2 case series,1 observational survey and 1 FDA MAUDE database adverse event report were included.
Other studies that were considered to be relevant to the procedure but were not included in the main summary of the key evidence are listed in the appendix.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions